New ACCM Supplement Now Available
Accessing Pulmonary Arterial Hypertension (PAH) Medication—It Takes a Village!
Pulmonary arterial hypertension affects only a small number of people but exacts a heavy toll, such that life expectancy after diagnosis is an average 7 years and the 1-year mortality rate is 15%. In the last 4 years, four new agents have been FDA-approved, making 13 drugs available to treat the illness. But it takes a village to care for a patient with PAH, and this special supplement to CareManagementfocuses on how the patient and their care team can work together to improve access to medications and provide patient education and support. Click here to read the supplement today!